tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Mersana Therapeutics Reports Q2 2025 Financial Results
PremiumCompany AnnouncementsMersana Therapeutics Reports Q2 2025 Financial Results
1M ago
Mersana Therapeutics price target adjusted to $17 at BTIG after reverse split
Premium
The Fly
Mersana Therapeutics price target adjusted to $17 at BTIG after reverse split
1M ago
Promising Progress and Strategic Focus Drive Buy Rating for Mersana Therapeutics
Premium
Ratings
Promising Progress and Strategic Focus Drive Buy Rating for Mersana Therapeutics
1M ago
Mersana Therapeutics Announces Reverse Stock Split
PremiumCompany AnnouncementsMersana Therapeutics Announces Reverse Stock Split
2M ago
Mersana Therapeutics announces 1-for-25 reverse stock split
Premium
The Fly
Mersana Therapeutics announces 1-for-25 reverse stock split
2M ago
Mersana Therapeutics’ XMT-1660 Study: A Potential Game-Changer in Cancer Treatment
Premium
Company Announcements
Mersana Therapeutics’ XMT-1660 Study: A Potential Game-Changer in Cancer Treatment
2M ago
Mersana Therapeutics Reports Positive Phase 1 Trial Results
PremiumCompany AnnouncementsMersana Therapeutics Reports Positive Phase 1 Trial Results
4M ago
Mersana Therapeutics reports additional interim Phase 1 data for Emi-Le
Premium
The Fly
Mersana Therapeutics reports additional interim Phase 1 data for Emi-Le
4M ago
Promising Clinical Trial Data and Upcoming Presentations Bolster Buy Rating for Mersana Therapeutics
Premium
Ratings
Promising Clinical Trial Data and Upcoming Presentations Bolster Buy Rating for Mersana Therapeutics
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100